AAO 2023: OTT166 progress: OcuTerra's diabetic retinopathy treatment
November 3rd 2023Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their innovative eye drop treatment, OTT166.
FDA grants Toku Breakthrough Device status for its cardiovascular risk AI platform
November 2nd 2023The company’s AI CLAIR technology platform has received FDA breakthrough device status, and if cleared by the FDA will deliver real-time cardiovascular disease risk assessments through routine eye exams.
AAO 2023: Phase 3 LYNX-1 trial: Phentolamine ophthalmic solution improves low-contrast night vision
November 2nd 2023Researchers conducted a study on 145 patients with night vision problems, testing the effects of 0.75% phentolamine ophthalmic solution. The trial demonstrated substantial improvement in visual acuity on both evaluation days.
Clearside Biomedical completes recruitment in ODYSSEY Phase 2b clinical trial of CLS-AX in wet AMD
November 1st 2023The clinical trial will evaluate the safety and efficacy of CLS-AX (axitinib injectable suspension), a tyrosine kinase inhibitor. According to the company, topline data is expected during the third quarter of 2024.
SpyGlass Pharma kicks off Phase I/II clinical trial of intraocular drug delivery platform
October 31st 2023According to the company, its Phase I/II trial is being initiated to investigate SpyGlass platform for the long-term delivery of bimatoprost in patients with glaucoma and visually significant cataracts.
ViaLase completes enrollment for VIA-002 trial of laser to treat POAG
October 30th 2023According to the company, its ViaLase Laser combines the precision of femtosecond laser technology and the accuracy of micron-level image guidance to deliver the world's first femtosecond laser image-guided high-precision trabeculotomy.